for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vectura Group PLC

VEC.L

Latest Trade

164.80GBp

Change

-0.20(-0.12%)

Volume

61,901

Today's Range

164.60

 - 

165.00

52 Week Range

100.00

 - 

176.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
165.00
Open
165.00
Volume
61,901
3M AVG Volume
126.15
Today's High
165.00
Today's Low
164.60
52 Week High
176.00
52 Week Low
100.00
Shares Out (MIL)
613.89
Market Cap (MIL)
1,012.92
Forward P/E
25.56
Dividend (Yield %)
--

Next Event

Full Year 2021 Vectura Group PLC Earnings Release

Latest Developments

More

FTSE Russell Says Vectura Group To Be Deleted From FTSE 250 After PMI Deal

Philip Morris Announces Satisfaction Of Japanese Antitrust Condition For Vectura Deal

Carlyle Waives Deadline For Timing Of Court Meeting, Vectura GM

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Vectura Group PLC

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.

Industry

Biotechnology & Drugs

Contact Info

Unit 1, Prospect West, Bumpers Way

SN14 6FH

United Kingdom

+44.1249.667700

http://www.vectura.com

Executive Leadership

Bruno F. J. Angelici

Non-Executive Chairman of the Board

William Downie

Chief Executive Officer, Executive Director

Paul Andrew Fry

Chief Financial Officer, Executive Director

Geraldine Venthoye

Chief Scientific Officer and Executive Vice President – Product Development

Joanne Hombal

Executive Vice President - Human Resources

Key Stats

2.20 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, GBP)

2018

0.2K

2019

0.2K

2020

0.2K

2021(E)

0.2K
EPS (GBp)

2018

5.083

2019

6.828

2020

7.452

2021(E)

6.439
Price To Earnings (TTM)
8.19
Price To Sales (TTM)
5.31
Price To Book (MRQ)
1.81
Price To Cash Flow (TTM)
5.89
Total Debt To Equity (MRQ)
0.77
LT Debt To Equity (MRQ)
0.55
Return on Investment (TTM)
23.37
Return on Equity (TTM)
20.46

Latest News

Latest News

UK's Vectura bows to sweetened 1.1 billion stg Philip Morris offer

Cigarette maker Philip Morris won the support of Vectura for its 1.1 billion pound ($1.5 billion) takeover offer for the inhaled treatments maker after outbidding private equity firm Carlyle, the British company said on Thursday.

Vectura takeover will not go to auction as Carlyle declares final bid

The takeover battle for British drugmaker Vectura Group will not go to auction on Wednesday after private equity firm Carlyle declared its 958 million pounds ($1.33 billion) bid as final before the deadline. ($1 = 0.7224 pounds) (Reporting by Yadarisa Shabong in Bengaluru)

British minister asks for monitoring of Vectura's proposed takeover by Philip Morris -The Times

British Business Minister Kwasi Kwarteng has asked officials to monitor drugmaker Vectura Group PLC's proposed takeover by U.S. tobacco group Philip Morris International Inc, the Times newspaper reported https://bit.ly/3efO4ag.

Cigarette maker Philip Morris to buy UK producer of respiratory treatments

Tobacco group Philip Morris International agreed on Friday to buy Vectura for 1.05 billions pounds ($1.44 billion), giving the U.S. firm access to the British drugmaker's respiratory ailment treatments and inhaling device technology.

Philip Morris to buy UK's Vectura for $1.44 billion

Cigarette maker Philip Morris International Inc said on Friday it will buy Vectura Group in a deal valuing the British pharmaceutical company at 1.05 billion pounds ($1.44 billion).

Strong earnings, Vectura boost British midcaps

London's FTSE 250 index edged higher on Wednesday, boosted by Marks & Spencer and Softcat Plc following positive earnings updates, while Vectura Group topped the mid-cap index after agreeing a takeover by The Carlyle Group.

UK pharma group Vectura agrees $1.4 billion takeover by Carlyle

Vectura Group, a British pharmaceutical company focused on inhaled medicines, said on Wednesday it had agreed a 958 million pound ($1.36 billion) takeover by global investment firm The Carlyle Group.

Vectura's $89.7 mln inhaler patent win against GSK upheld

GlaxoSmithKline PLC has lost an appeal seeking to overturn an $89.7 million verdict a jury handed down after finding that the company's Ellipta line of inhalers infringed a patent belonging to rival drug company Vectura Ltd.

BRIEF-Vectura Group Says Enerzair Breezhaler Gets Regulatory Nod

* VECTURA GROUP PLC - ENERZAIR® BREEZHALER® RECEIVES REGULATORY APPROVAL

BRIEF-Vectura Group Signs Global Licence And Development Agreement With Aerami Therapeutics

* VECTURA GROUP PLC - SIGNING OF A GLOBAL LICENCE AND DEVELOPMENT AGREEMENT WITH AERAMI THERAPEUTICS

BRIEF-Vectura Group Maintains 2020 Outlook

* VECTURA GROUP PLC - AGM TRADING UPDATE & REITERATION OF 2020 GUIDANCE

BRIEF-Vectura Says Upon European Regulatory Approval Of QVM149, Eligible To Get $5 Mln Milestone

* FINAL DECISION FROM EUROPEAN COMMISSION FOR GRANT OF MARKETING AUTHORISATION EXPECTED BE RECEIVED ABOUT 2 MONTHS AFTER CHMP OPINION

BRIEF-Vectura Says It Has Not Seen Any Impact To Its Business From Covid-19

* VECTURA GROUP PLC - AT THIS TIME, VECTURA HAS NOT SEEN ANY IMPACT TO ITS BUSINESS FROM COVID-19

BRIEF-Vectura Group FY Gross Profit 95.3 Mln Stg Vs 98.9 Mln Stg

* VECTURA HAS NOT SEEN ANY IMPACT TO ITS BUSINESS FROM THE CORONAVIRUS OUTBREAK

BRIEF-Sixt SE Says Consolidated Earnings Before Taxes For FY 2019 Are Expected About Eur 337 Mln

* DGAP-ADHOC: SIXT SE: SIXT SE PUBLISHES OUTLOOK FOR FINANCIAL YEAR 2020 - MANAGING BOARD RESOLVES PROPOSAL TO SUSPEND DIVIDEND PAYMENT AND TO IMPLEMENT FURTHER MEASURES TO LIMIT THE FINANCIAL IMPACT OF THE CORONA CRISIS

Vectura, Sandoz win ruling on inhaler packaging case against GSK

Vectura Group said on Friday a British court had ruled in its favor on the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline.

Vectura, Sandoz gets favourable ruling in inhaler packaging case against GSK

Vectura Group said on Friday a British court had ruled in its and partner Sandoz's favour over the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline.

UPDATE 1-Drugmaker Vectura parts ways with CEO Ward-Lilley

British drugmaker Vectura Group Plc's chief executive officer James Ward-Lilley will step down at the end of this month, the company said on Monday, saying it had agreed with the industry veteran that a change of leadership was needed.

Drugmaker Vectura CEO James Ward-Lilley to step down

British drugmaker Vectura Group Plc's chief executive officer, James Ward-Lilley, will step down by the end of this month, the company said on Monday.

BRIEF-Vectura Group To Receive $2.5 Mln Milestone Payment For QVM149 Submission

* WILL RECEIVE A $2.5MILLION MILESTONE PAYMENT UNDER AN EXCLUSIVE LICENCE AGREEMENT WITH NOVARTIS AG Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up